Merck Stocks Rise 2.6% With Qlex Still Under 10% of Keytruda Sales

What happened

Merck shares climbed 2.59% to $150.13 after JPMorgan raised its price target to $175 from $165 while keeping an Overweight rating. Third-quarter sales were $18.085 billion, with Keytruda and Keytruda Qlex together generating about $8.6 billion, and Qlex contributing $830 million.

Confirmed

Global impact / market context

Keytruda and Qlex supply nearly 48% of company sales, so Merck depends heavily on one drug family. The newer Qlex version brought in $830 million, but investors must judge whether it adds new patient demand or mainly moves existing Keytruda sales, which affects future revenue growth.

Analyst inference

The higher price target signals analyst confidence, yet a price-to-earnings ratio of 120 means investors pay a lot for each dollar of profit, which means expectations are high. Nine medium warning signs and uneven growth drivers add risk if Keytruda revenue slows.

Analyst inference

What to watch

1. Watch whether Qlex revenue of $830 million grows in coming quarters or stays close to 10% of the combined Keytruda franchise, since that shows if it adds new business. Confirmed
2. Merck should clarify how much Qlex demand comes from new patients rather than existing Keytruda users, which would show whether the company gains extra sales or shifts them. Proposed
3. Track growth from Winrevair, which contributed $694 million, because stronger sales outside Keytruda would reduce Merck's dependence on a single drug family for revenue. Analyst inference

Evidence

• gurufocus.com